Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non–Small Cell Lung Cancer: A Case Report

Letters20 December 2016Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non–Small Cell Lung Cancer: A Case ReportKonstantinos Syrigos, PhD, Sofia Tsagouli, MD, and Dimitra Grapsa, PhDKonstantinos Syrigos, PhDFrom "Sotiria" Athens General Hospital, University of Athens School of Medicine, Athens, Greece., Sofia Tsagouli, MDFrom "Sotiria" Athens General Hospital, University of Athens School of Medicine, Athens, Greece., and Dimitra Grapsa, PhDFrom "Sotiria" Athens General Hospital, University of Athens School of Medicine, Athens, Greece.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0137 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Nivolumab (Opdivo, Bristol-Myers Squibb) is a human IgG4 monoclonal antibody with high affinity for the programmed death-1 receptor and is the first programmed death-1 immune checkpoint inhibitor approved by the U.S. Food and Drug Administration for second-line treatment of patients with advanced squamous and nonsquamous non–small cell lung cancer (1). Because of its "unbalancing" effect on the immune system, nivolumab may trigger immune-related adverse events (IRAEs), especially among patients with an autoimmune predisposition (2).Objective: To present a case of nivolumab-induced recurrence of rheumatoid arthritis successfully treated with concurrent administration of prednisolone in a patient with advanced non–small cell ...References1. Guibert N, Mazières J. Nivolumab for treating non-small cell lung cancer. Expert Opin Biol Ther. 2015;15:1789-97. [PMID: 26574148] doi:10.1517/14712598.2015.1114097 CrossrefMedlineGoogle Scholar2. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48. [PMID: 26765102] doi:10.1016/j.ejca.2015.11.016 CrossrefMedlineGoogle Scholar3. Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park). 2014;28 Suppl 3:30-8. [PMID: 25384885] MedlineGoogle Scholar4. Narita T, Oiso N, Taketomo Y, Okahashi K, Yamauchi K, Sato M, et al. Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol. 2016;43:210-4. [PMID: 26198822] doi:10.1111/1346-8138.13028 CrossrefMedlineGoogle Scholar5. Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016;26:202-4. [PMID: 26795275] doi:10.1097/CMR.0000000000000232 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From "Sotiria" Athens General Hospital, University of Athens School of Medicine, Athens, Greece.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0137. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseasesImmune checkpoint inhibitor–induced inflammatory arthritis as a model of autoimmune arthritisMolecular mechanisms underlying rheumatoid arthritis and cancer development and treatmentNivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric AdenocarcinomaA Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the LiteratureUltrasound-Proven Severe Synovitis Induced by PD-1 Inhibitor Therapy in a Patient Predisposed to Seronegative Inflammatory ArthritisNivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature reviewPrevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysisReleasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancerNivolumab 20 December 2016Volume 165, Issue 12Page: 894-895KeywordsArthritisClinical trialsDrugsLung and intrathoracic tumorsPatientsRespiratory system proceduresRheumatoid arthritisThoraxThyroidToxicity ePublished: 20 December 2016 Issue Published: 20 December 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...